Benjamin F. Edwards & Company, Inc. Veracyte, Inc. Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Veracyte, Inc. stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 29,248 shares of VCYT stock, worth $1.2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
29,248
Previous 501
5737.92%
Holding current value
$1.2 Million
Previous $11,000
5663.64%
% of portfolio
0.01%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding VCYT
# of Institutions
307Shares Held
81.7MCall Options Held
134KPut Options Held
13.3K-
Black Rock Inc. New York, NY7.79MShares$319 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.75MShares$317 Million0.0% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI5.02MShares$205 Million0.27% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl4.92MShares$201 Million1.59% of portfolio
-
Wellington Management Group LLP Boston, MA4.23MShares$173 Million0.03% of portfolio
About VERACYTE, INC.
- Ticker VCYT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,575,904
- Market Cap $2.93B
- Description
- Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...